Amphastar Pharmaceuticals
Market Cap
US$1.1b
Last Updated
2019/08/23 00:13 UTC
Data Sources
Company Financials +
Executive Summary
Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and France.
Snowflake
Fundamentals
Flawless balance sheet and fair value.
Similar Companies
Share Price & News
How has Amphastar Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
5.5%
NasdaqGS:AMPH
1.9%
US Pharmaceuticals
2.1%
US Market
1 Year Return
25.2%
NasdaqGS:AMPH
-6.0%
US Pharmaceuticals
-0.04%
US Market
AMPH outperformed the Pharmaceuticals industry which returned -5.8% over the past year.
AMPH outperformed the Market in United States of America which returned 0.2% over the past year.
Share holder returns
| AMPH | Industry | Market | |
|---|---|---|---|
| 7 Day | 5.5% | 1.9% | 2.1% |
| 30 Day | 15.3% | -1.7% | -3.2% |
| 90 Day | 6.4% | -3.5% | 2.8% |
| 1 Year | 25.2%25.2% | -3.7%-6.0% | 2.2%-0.04% |
| 3 Year | 16.0%16.0% | 11.3%3.7% | 41.5%32.3% |
| 5 Year | 86.6%86.6% | 23.4%10.4% | 55.0%37.8% |
Price Volatility Vs. Market
How volatile is Amphastar Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 days ago | Simply Wall St
Is Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) ROE Of 11% Concerning?3 weeks ago | Simply Wall St
Investors Who Bought Amphastar Pharmaceuticals (NASDAQ:AMPH) Shares Five Years Ago Are Now Up 101%1 month ago | Simply Wall St
Is Amphastar Pharmaceuticals (NASDAQ:AMPH) A Risky Investment?Valuation
Is Amphastar Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?
>50%
Discount to future cash flow value
Intrinsic Value Based on Future Cash Flows
Amphastar Pharmaceuticals's share price is below the future cash flow value, and at a moderate discount (> 20%).
Amphastar Pharmaceuticals's share price is below the future cash flow value, and at a substantial discount (> 40%).
Price Based on Earnings
Amphastar Pharmaceuticals is overvalued based on earnings compared to the US Pharmaceuticals industry average.
Amphastar Pharmaceuticals is overvalued based on earnings compared to the United States of America market.
Price Based on Expected Growth
Unable to calculate PEG ratio for Amphastar Pharmaceuticals, we can't assess if its growth is good value.
Price Based on Value of Assets
Amphastar Pharmaceuticals is good value based on assets compared to the US Pharmaceuticals industry average.
Next Steps
Future Growth
How is Amphastar Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 6 analysts?
14.2%
Forecasted annual revenue growth
Earnings and Revenue Growth Estimates
Future Annual Growth Analysis
Amphastar Pharmaceuticals's revenue is expected to grow by 14.2% yearly, however this is not considered high growth (20% yearly).
Amphastar Pharmaceuticals's earnings are expected to decrease over the next 1-3 years, this is not considered high growth.
Amphastar Pharmaceuticals's revenue growth is expected to exceed the United States of America market average.
Amphastar Pharmaceuticals's earnings are expected to decrease over the next 1-3 years, this is below the United States of America market average.
Amphastar Pharmaceuticals's earnings are expected to decrease over the next 1-3 years, this is below the low risk savings rate of 2.7%.
Earnings per Share Growth Estimates
Future Return on Equity
Unable to establish if Amphastar Pharmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
Next Steps
Past Performance
How has Amphastar Pharmaceuticals performed over the past 5 years?
40.5%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Amphastar Pharmaceuticals has delivered over 20% year on year earnings growth in the past 5 years.
Amphastar Pharmaceuticals has become profitable in the last year making the earnings growth rate difficult to compare to the 5-year average.
Amphastar Pharmaceuticals has become profitable in the last year making it difficult to compare the US Pharmaceuticals industry average.
Return on Equity
Amphastar Pharmaceuticals has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
Return on Assets
Amphastar Pharmaceuticals used its assets less efficiently than the US Pharmaceuticals industry average last year based on Return on Assets.
Return on Capital Employed
Amphastar Pharmaceuticals's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
Next Steps
Financial Health
How is Amphastar Pharmaceuticals's financial position?
Financial Position Analysis
Amphastar Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Amphastar Pharmaceuticals's cash and other short term assets cover its long term commitments.
Debt to Equity History and Analysis
Amphastar Pharmaceuticals's level of debt (10.8%) compared to net worth is satisfactory (less than 40%).
The level of debt compared to net worth has been reduced over the past 5 years (18.6% vs 10.8% today).
Debt is well covered by operating cash flow (157.1%, greater than 20% of total debt).
Amphastar Pharmaceuticals earns more interest than it pays, coverage of interest payments is not a concern.
Balance Sheet
High level of physical assets or inventory.
Debt is covered by short term assets, assets are 6.1x debt.
Next Steps
Dividend
What is Amphastar Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield and Payments Analysis
Unable to evaluate Amphastar Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
Unable to evaluate Amphastar Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Unable to perform a dividend volatility check as Amphastar Pharmaceuticals has not reported any payouts.
Unable to verify if Amphastar Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to Shareholders
Unable to calculate sustainability of dividends as Amphastar Pharmaceuticals has not reported any payouts.
Future Payout to Shareholders
Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
Next Steps
Management
What is the CEO of Amphastar Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?
10.4yrs
Average management tenure
CEO
Jack Zhang (72yo)
23.6yrs
Tenure
US$5,874,707
Compensation
Dr. Yongfeng Zhang, also known as Jack, Ph.D., co-founded Amphastar Pharmaceuticals in 1996 and has been its Chief Executive Officer and Chief Science Officer since 1996 and 2005 respectively and served as ...
CEO Compensation Analysis
Jack's remuneration is higher than average for companies of similar size in United States of America.
Jack's compensation has increased in line with Amphastar Pharmaceuticals recently becoming profitable.
Management Age and Tenure
10.4yrs
Average Tenure
60yo
Average Age
The average tenure for the Amphastar Pharmaceuticals management team is over 5 years, this suggests they are a seasoned and experienced team.
Board Age and Tenure
16.0yrs
Average Tenure
70.5yo
Average Age
The average tenure for the Amphastar Pharmaceuticals board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Insider Trading
Amphastar Pharmaceuticals individual insiders have only sold shares in the past 3 months.
Recent Insider Transactions
| Entity | Individual |
| Role | Chief Financial Officer CFO, Treasurer & Senior VP of Finance |
| Shares | 4,942 |
| Max Price | US$21.00 |
| Entity | Individual |
| Role | Member of the Board of Directors Independent Director |
| Shares | 1,616 |
| Max Price | US$20.65 |
| Entity | Individual |
| Role | Chief Executive Officer CEO, Chief Science Officer & Director |
| Shares | 43,577 |
| Max Price | US$20.48 |
| Entity | Company |
| Shares | 133,915 |
| Max Price | US$22.13 |
| Entity | Individual |
| Role | Head of Sales Senior VP of Corporate Administration Center |
| Shares | 2,480 |
| Max Price | US$21.48 |
| Entity | Individual |
| Role | Head of Sales Senior VP of Corporate Administration Center |
| Shares | 1,520 |
| Max Price | US$20.49 |
| Entity | Individual |
| Role | Head of Sales Senior VP of Corporate Administration Center |
| Shares | 1,299 |
| Max Price | US$20.26 |
Ownership Breakdown
Management Team
Bill Peters (51yo)
CFO, Treasurer & Senior VP of Finance
- Tenure: 5.3yrs
Jack Zhang (72yo)
CEO, Chief Science Officer & Director
- Tenure: 23.6yrs
- Compensation: US$5.87m
Mary Luo (69yo)
Chairman of the Board
- Tenure: 23.6yrs
- Compensation: US$3.03m
Peter Langosh (66yo)
Vice President of Operational Improvement and Vice President of Internal Audit
- Tenure: 18.6yrs
- Compensation: US$162.64k
Eva Wen
Director of System Control
- Tenure: 14.6yrs
Jason Shandell (45yo)
President
- Tenure: 9.6yrs
- Compensation: US$2.58m
Rong Zhou (60yo)
Executive VP of Production & President of Armstrong
- Tenure: 4.2yrs
Jacob Liawatidewi (45yo)
Senior VP of Corporate Administration Center
- Tenure: 5.7yrs
Board Members
Michael Zasloff (73yo)
Lead Independent Director
- Tenure: 3.6yrs
- Compensation: US$300.00k
Richard Prins (62yo)
Independent Director
- Tenure: 17.5yrs
- Compensation: US$293.00k
Howard Lee (58yo)
Independent Director
- Tenure: 12.0yrs
- Compensation: US$299.50k
Jack Zhang (72yo)
CEO, Chief Science Officer & Director
- Tenure: 23.6yrs
- Compensation: US$5.87m
Chen Yang
Member of Scientific Advisory Board
- Tenure: 0.0yrs
Paul White
Member of Scientific Advisory Board
- Tenure: 0.0yrs
Gordon Treweek (76yo)
Member of Scientific Advisory Board
- Tenure: 0.0yrs
Mary Luo (69yo)
Chairman of the Board
- Tenure: 23.6yrs
- Compensation: US$3.03m
Richard Koo (78yo)
Independent Director
- Tenure: 16.0yrs
- Compensation: US$300.00k
Jason Shandell (45yo)
President
- Tenure: 9.6yrs
- Compensation: US$2.58m
Company Information
Amphastar Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Amphastar Pharmaceuticals, Inc.
- Ticker: AMPH
- Exchange: NasdaqGS
- Founded: 1996
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$1.065b
- Shares outstanding: 47.23m
- Website: https://www.amphastar.com
Number of Employees
Location
- Amphastar Pharmaceuticals, Inc.
- 11570 6th Street
- Rancho Cucamonga
- California
- 91730
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| AMPH | NasdaqGS (Nasdaq Global Select) | Yes | Common Stock | US | USD | Jun 2014 |
| 29A | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Jun 2014 |
Biography
Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States  ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/08/23 00:13 |
| End of Day Share Price | 2019/08/22 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.